ION Geophysical Corporation (IO) Income Statement Analysis

See more : Jia Group Holdings Limited (8519.HK) Income Statement Analysis – Financial Results

Complete financial analysis of ION Geophysical Corporation (IO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ION Geophysical Corporation, a leading company in the Oil & Gas Equipment & Services industry within the Energy sector.

You may be interested

ION Geophysical Corporation (IO)

Industry: Oil & Gas Equipment & Services

Sector: Energy

Website: https://www.iongeo.com

About ION Geophysical Corporation

ION Geophysical Corporation provides data-driven decision-making to offshore energy, and ports, and defense industries worldwide. The company operates through two segments, E&P Technology & Services and Operations Optimization. The E&P Technology & Services segment creates digital data assets and delivers services to help E&P companies improve decision-making and reduce risk. This segment includes two synergistic groups, imaging and reservoir services, and ventures. The company's Imaging and Reservoir Services group provides data processing, imaging, and reservoir services that improve image quality and subsurface insights, helping E&P companies reduce exploration and production risk, evaluate and develop reservoirs, and increase production. Its Imaging and Reservoir Services group develops and applies proprietary processing algorithms through its imaging engine to data owned or licensed by its customers to translate raw data into subsurface images. The Operations Optimization segment develops mission-critical subscription offerings and provides engineering services that enable operational control and optimization offshore. This segment includes the company's Optimization Software & Services and Devices offerings. The company's Optimization Software & Services group provides survey design, command, and control software systems and related services for marine towed streamer and seabed operations. Its Devices offerings group develops intelligent equipment controlled by its software to optimize operations. The company sells its services and products through a direct sales force consisting of employees and international third-party sales representatives. ION Geophysical Corporation was formerly known as Input/Output, Inc. and changed its name to ION Geophysical Corporation in 2007. The company was founded in 1968 and is headquartered in Houston, Texas. On April 12, 2022, ION Geophysical Corporation along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas.

Metric	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999	1998	1997	1996	1995	1994	1993	1992	1991	1990
Revenue	122.67M	174.68M	180.05M	197.55M	172.81M	221.51M	509.56M	549.17M	526.32M	454.62M	444.32M	419.78M	679.52M	713.11M	503.56M	362.68M	247.30M	150.03M	118.58M	212.05M	78.32M	197.40M	385.90M	281.80M	278.30M	134.70M	95.80M	54.20M	45.50M	36.00M	28.80M
Cost of Revenue	81.02M	114.66M	120.43M	121.92M	136.78M	213.51M	447.34M	389.85M	310.52M	281.18M	278.59M	287.64M	471.78M	510.19M	349.34M	256.31M	175.71M	121.13M	99.62M	135.80M	47.11M	199.20M	215.20M	174.80M	156.20M	67.20M	48.10M	24.80M	21.90M	17.20M	13.30M
Gross Profit	41.66M	60.02M	59.62M	75.64M	36.03M	8.00M	62.22M	159.31M	215.80M	173.45M	165.73M	132.14M	207.75M	202.92M	154.22M	106.38M	71.59M	28.90M	18.96M	76.25M	31.21M	-1.80M	170.70M	107.00M	122.10M	67.50M	47.70M	29.40M	23.60M	18.80M	15.50M
Gross Profit Ratio	33.96%	34.36%	33.11%	38.29%	20.85%	3.61%	12.21%	29.01%	41.00%	38.15%	37.30%	31.48%	30.57%	28.46%	30.63%	29.33%	28.95%	19.26%	15.99%	35.96%	39.85%	-0.91%	44.23%	37.97%	43.87%	50.11%	49.79%	54.24%	51.87%	52.22%	53.82%
Research & Development	12.97M	19.03M	18.18M	16.43M	17.83M	26.45M	41.01M	37.74M	34.08M	24.57M	25.23M	44.86M	49.54M	46.30M	32.75M	20.27M	19.61M	18.70M	28.76M	29.44M	16.05M	42.80M	33.00M	23.00M	23.20M	11.40M	7.90M	0.00	0.00	0.00	0.00
General & Administrative	27.46M	42.25M	37.36M	47.13M	44.00M	51.70M	76.18M	66.59M	71.95M	50.81M	57.25M	72.51M	118.75M	92.98M	81.46M	61.39M	53.51M	29.32M	30.38M	33.97M	8.13M	95.10M	42.90M	33.80M	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Selling & Marketing	11.68M	23.21M	21.79M	20.78M	17.37M	30.49M	39.68M	38.58M	35.24M	31.27M	30.41M	34.95M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.93M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	39.13M	65.46M	59.16M	67.91M	61.37M	82.19M	115.86M	105.18M	107.19M	82.08M	87.66M	107.46M	118.75M	92.98M	81.46M	61.39M	53.51M	29.32M	30.38M	33.97M	14.06M	95.10M	42.90M	33.80M	31.10M	19.00M	13.80M	15.20M	11.50M	8.70M	7.90M
Other Expenses	0.00	0.00	0.00	4.16M	-5.15M	-101.98M	-69.56M	183.33M	0.00	0.00	0.00	0.00	-381.11M	-253.00K	58.00K	99.00K	-3.98M	1.12M	23.39M	4.94M	2.76M	22.20M	17.30M	13.20M	11.90M	5.60M	3.30M	1.90M	1.10M	1.10M	1.10M
Operating Expenses	52.10M	84.48M	77.34M	88.49M	74.05M	6.66M	87.31M	326.24M	141.27M	106.65M	112.89M	152.31M	-212.82M	139.03M	114.27M	81.76M	69.14M	49.14M	82.52M	68.35M	32.87M	160.10M	93.20M	70.00M	66.20M	36.00M	25.00M	17.10M	12.60M	9.80M	9.00M
Cost & Expenses	133.11M	199.14M	197.76M	210.41M	210.83M	220.17M	534.65M	716.10M	451.79M	387.83M	391.48M	439.95M	258.95M	649.22M	463.61M	338.07M	244.84M	170.27M	182.15M	204.15M	79.98M	359.30M	308.40M	244.80M	222.40M	103.20M	73.10M	41.90M	34.50M	27.00M	22.30M
Interest Income	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.72M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest Expense	13.81M	13.07M	12.97M	16.71M	18.49M	18.75M	19.38M	12.34M	5.27M	5.78M	0.00	35.67M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Depreciation & Amortization	26.30M	43.20M	57.75M	63.69M	55.31M	62.31M	92.03M	104.87M	105.28M	13.92M	110.74M	96.36M	113.58M	64.43M	47.05M	36.70M	25.59M	11.22M	28.78M	17.78M	11.65M	22.20M	17.30M	13.20M	11.90M	5.60M	3.30M	1.90M	1.10M	1.10M	1.10M
EBITDA	18.49M	16.14M	2.27M	50.19M	13.07M	59.99M	3.74M	-102.92M	197.72M	54.61M	100.84M	1.99M	-106.32M	119.90M	81.50M	56.85M	23.32M	-11.58M	-33.18M	30.25M	2.68M	-133.10M	101.00M	37.50M	68.30M	41.00M	27.30M	15.20M	12.90M	9.80M	6.70M
EBITDA Ratio	15.07%	9.24%	1.26%	25.40%	7.56%	27.08%	0.73%	-18.74%	37.57%	12.01%	22.70%	0.47%	-15.65%	16.81%	16.19%	15.67%	9.43%	-7.72%	-27.98%	14.27%	3.42%	-67.43%	26.17%	13.31%	24.54%	30.44%	28.50%	28.04%	28.35%	27.22%	23.26%
Operating Income	-7.80M	-27.06M	-55.48M	-13.51M	-42.24M	-2.33M	-88.29M	-207.80M	92.44M	40.69M	-9.90M	-94.37M	-219.91M	55.47M	34.46M	20.15M	-2.28M	-22.80M	-61.96M	12.47M	-8.97M	-155.30M	83.70M	24.30M	56.40M	35.40M	24.00M	13.30M	11.80M	8.70M	5.60M
Operating Income Ratio	-6.36%	-15.49%	-30.82%	-6.84%	-24.44%	-1.05%	-17.33%	-37.84%	17.56%	8.95%	-2.23%	-22.48%	-32.36%	7.78%	6.84%	5.55%	-0.92%	-15.20%	-52.25%	5.88%	-11.46%	-78.67%	21.69%	8.62%	20.27%	26.28%	25.05%	24.54%	25.93%	24.17%	19.44%
Total Other Income/Expenses	-13.69M	-12.09M	-12.20M	-15.84M	-18.06M	-18.79M	-18.65M	-13.00M	-5.75M	-5.99M	0.00	-35.67M	0.00	0.00	-398.00K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Income Before Tax	-21.50M	-39.15M	-67.68M	-29.35M	-60.31M	-21.11M	-106.94M	-220.80M	86.68M	34.70M	-9.90M	-130.04M	-219.91M	55.47M	34.06M	20.15M	-2.28M	-22.80M	-61.96M	12.47M	-8.97M	-155.30M	83.70M	24.30M	56.40M	35.40M	24.00M	13.30M	11.80M	8.70M	5.60M
Income Before Tax Ratio	-17.52%	-22.41%	-37.59%	-14.86%	-34.90%	-9.53%	-20.99%	-40.21%	16.47%	7.63%	-2.23%	-30.98%	-32.36%	7.78%	6.76%	5.55%	-0.92%	-15.20%	-52.25%	5.88%	-11.46%	-78.67%	21.69%	8.62%	20.27%	26.28%	25.05%	24.54%	25.93%	24.17%	19.44%
Income Tax Expense	15.62M	8.06M	2.72M	24.00K	4.42M	4.04M	20.58M	25.72M	23.86M	10.14M	26.94M	-19.99M	1.13M	12.82M	5.11M	1.37M	701.00K	348.00K	57.92M	3.13M	1.33M	-49.70M	26.80M	7.70M	17.70M	10.90M	7.40M	4.20M	4.00M	3.00M	1.90M
Net Income	-37.11M	-47.21M	-70.40M	-29.38M	-64.73M	-25.15M	-127.52M	-246.52M	62.83M	24.57M	-36.84M	-110.06M	-221.04M	42.64M	28.94M	18.78M	-2.98M	-23.15M	-119.87M	9.34M	-10.31M	-105.60M	56.90M	16.60M	38.70M	24.50M	16.60M	9.10M	7.80M	5.70M	3.70M
Net Income Ratio	-30.25%	-27.03%	-39.10%	-14.87%	-37.46%	-11.36%	-25.03%	-44.89%	11.94%	5.40%	-8.29%	-26.22%	-32.53%	5.98%	5.75%	5.18%	-1.20%	-15.43%	-101.09%	4.41%	-13.16%	-53.50%	14.74%	5.89%	13.91%	18.19%	17.33%	16.79%	17.14%	15.83%	12.85%
EPS	-2.60	-3.34	-5.14	-2.47	-5.68	-2.30	-11.66	-23.33	6.05	2.38	-3.83	-14.94	-34.58	7.81	5.46	3.58	-0.68	-6.78	-35.25	2.74	-3.04	-32.63	19.41	5.68	14.12	10.13	7.01	4.56	4.03	2.94	0.64
EPS Diluted	-2.60	-3.34	-5.14	-2.47	-5.68	-2.30	-11.66	-23.33	5.79	2.36	-3.83	-14.94	-34.58	6.57	4.56	3.53	-0.68	-6.78	-35.25	2.68	-3.04	-32.63	19.21	5.68	14.12	10.13	7.01	4.56	4.03	2.94	0.64
Weighted Avg Shares Out	14.27M	14.13M	13.69M	11.88M	11.40M	10.96M	10.94M	10.57M	10.39M	10.32M	9.62M	7.37M	6.39M	5.46M	5.30M	5.24M	4.40M	3.42M	3.40M	3.41M	3.39M	3.24M	2.93M	2.92M	2.74M	2.42M	2.37M	2.00M	1.94M	1.94M	5.80M
Weighted Avg Shares Out (Dil)	14.27M	14.13M	13.69M	11.88M	11.40M	10.96M	10.94M	10.57M	10.85M	10.41M	9.62M	7.37M	6.39M	6.49M	6.35M	5.32M	4.40M	3.42M	3.40M	3.49M	3.39M	3.24M	2.96M	2.92M	2.74M	2.42M	2.37M	2.00M	1.94M	1.94M	5.80M

IMFINZI® (durvalumab) granted Priority Review in the US for patients with muscle-invasive bladder cancer

December 6, 2024businesswire.com

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's supplemental Biologics License Application (sBLA) for IMFINZI® (durvalumab) has been accepted and granted Priority Review in the US for the treatment of patients with muscle-invasive bladder cancer (MIBC). The Food and Drug Administration (FDA) grants Priority Review...

IMFINZI® (durvalumab) demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase III trial

June 25, 2024businesswire.com

WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the NIAGARA Phase III trial showed AstraZeneca's IMFINZI® (durvalumab) in combination with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of event-free survival (EFS) and the key secondary endpoint...

IMFINZI® (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial

April 5, 2024businesswire.com

WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results of the ADRIATIC Phase III trial showed AstraZeneca's IMFINZI® (durvalumab) demonstrated a statistically significant and clinically meaningful improvement in the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) in patients with limited-stage...